Literature DB >> 3580959

Definition of subclasses of adenosine receptors associated with adenylate cyclase: interaction of adenosine analogs with inhibitory A1 receptors and stimulatory A2 receptors.

D Ukena, R A Olsson, J W Daly.   

Abstract

The structure-activity relationships of 63 adenosine analogs as agonists for the A1 adenosine receptors that mediate inhibition of adenylate cyclase activity in rat fat cells and for the A2 adenosine receptors that mediate stimulation of adenylate cyclase in rat pheochromocytoma PC12 cells and human platelets were determined. The lack of correspondence between the structure-activity relationships of these analogs at the A1 and A2 receptors appear definitive in terms of establishing the existence of A1 and A2 subclasses of adenosine receptors. However, significant differences in the agonist profiles at A2 receptors of platelet and PC12 indicate a certain degree of structural heterogeneity within the members of the A2 adenosine receptor subclass. Whether such differences are due to different species or different cell types is not known. A set of adenosine analogs, such as N6-cyclohexyl-, N6-R-, and S-1-phenyl-2- propyladenosines, 5'-N-ethylcarboxamidoadenosine and its N6-cyclohexyl derivative, 2-chloroadenosine, and 2-phenylaminoadenosine, appear to represent a series of analogs useful for pharmacological characterization of A1 and A2 classes of adenosine receptors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3580959     DOI: 10.1139/y87-063

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  15 in total

1.  Adenosine in heart and lung disease. Proceedings of the first Cardiothoracic Institute Workshop. 30 March 1988, London. Abstracts.

Authors: 
Journal:  Postgrad Med J       Date:  1988-10       Impact factor: 2.401

2.  Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.

Authors:  C Gallo-Rodriguez; X D Ji; N Melman; B D Siegman; L H Sanders; J Orlina; B Fischer; Q Pu; M E Olah; P J van Galen
Journal:  J Med Chem       Date:  1994-03-04       Impact factor: 7.446

3.  Adenosine Receptors: The Contributions by John W. Daly.

Authors:  Bertil B Fredholm; Kenneth A Jacobson
Journal:  Heterocycles       Date:  2009       Impact factor: 0.831

4.  Inhibition of platelet aggregation by adenosine receptor agonists.

Authors:  G Cristalli; S Vittori; R D Thompson; W L Padgett; D Shi; J W Daly; R A Olsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-06       Impact factor: 3.000

5.  Stimulation of chloride secretion by P1 purinoceptor agonists in cystic fibrosis phenotype airway epithelial cell line CFPEo-.

Authors:  A C Chao; J B Zifferblatt; J A Wagner; Y J Dong; D C Gruenert; P Gardner
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

6.  Partial agonism of theophylline-7-riboside on adenosine receptors.

Authors:  A P IJzerman; E M van der Wenden; J K von Frijtag Drabbe Künzel; R A Mathôt; M Danhof; P A Borea; K Varani
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-12       Impact factor: 3.000

7.  A2A adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: characterization with radioligand binding and by activation of adenylate cyclase.

Authors:  I Hide; W L Padgett; K A Jacobson; J W Daly
Journal:  Mol Pharmacol       Date:  1992-02       Impact factor: 4.436

8.  Adenosine analogs with covalently attached lipids have enhanced potency at A1-adenosine receptors.

Authors:  K A Jacobson; J Zimmet; R Schulick; S Barone; J W Daly; K L Kirk
Journal:  FEBS Lett       Date:  1987-12-10       Impact factor: 4.124

9.  Characterization of the adenosine receptors of the rat superior cervical ganglion.

Authors:  G P Connolly; T W Stone; F Brown
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

10.  Characterization of adenosine receptors in guinea-pig isolated left atria.

Authors:  U Jahnel; H Nawrath
Journal:  Br J Pharmacol       Date:  1989-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.